<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lugano and Paris staging systems for gastrointestinal lymphomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lugano and Paris staging systems for gastrointestinal lymphomas</h1>
<div class="graphic"><div class="figure"><div class="ttl">Lugano and Paris staging systems for gastrointestinal lymphomas</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup width="90%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Paris staging system for primary gastrointestinal lymphomas*<sup>¶</sup><sup>[1]</sup></td> </tr> <tr> <td class="indent1" colspan="2"><strong>Primary tumor (T)</strong></td> </tr> <tr> <td class="indent2">TX</td> <td>Lymphoma extent not specified</td> </tr> <tr> <td class="indent2">T0</td> <td>No evidence of lymphoma</td> </tr> <tr> <td class="indent2">T1</td> <td>Lymphoma confined to the mucosa/submucosa</td> </tr> <tr> <td class="indent2">T1m</td> <td>Lymphoma confined to the mucosa</td> </tr> <tr> <td class="indent2">T1sm</td> <td>Lymphoma confined to the submucosa</td> </tr> <tr> <td class="indent2">T2</td> <td>Lymphoma infiltrates muscularis propria or subserosa</td> </tr> <tr> <td class="indent2">T3</td> <td>Lymphoma penetrates serosa (visceral peritoneum) without invasion of adjacent structures</td> </tr> <tr class="divider_bottom"> <td class="indent2">T4</td> <td>Lymphoma invades adjacent structures or organs</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Regional lymph node involvement (N)</strong></td> </tr> <tr> <td class="indent2">NX</td> <td>Involvement of lymph nodes not assessed</td> </tr> <tr> <td class="indent2">N0</td> <td>No evidence of lymph node involvement</td> </tr> <tr> <td class="indent2">N1<sup>Δ</sup></td> <td>Involvement of regional lymph nodes</td> </tr> <tr> <td class="indent2">N2</td> <td>Involvement of intra-abdominal lymph nodes beyond the regional area</td> </tr> <tr class="divider_bottom"> <td class="indent2">N3</td> <td>Spread to extra-abdominal lymph nodes</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Distant metastasis (M)</strong></td> </tr> <tr> <td class="indent2">MX</td> <td>Dissemination of lymphoma not assessed</td> </tr> <tr> <td class="indent2">M0</td> <td>No evidence of extranodal dissemination</td> </tr> <tr> <td class="indent2">M1</td> <td>Non-continuous involvement of separate site in gastrointestinal tract (eg, stomach and rectum)</td> </tr> <tr class="divider_bottom"> <td class="indent2">M2</td> <td>Non-continuous involvement of other tissues (eg, peritoneum, pleura) or organs (eg, tonsils, parotid gland, ocular adnexa, lung, liver, spleen, kidney, breast)</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Bone marrow involvement (B)</strong></td> </tr> <tr> <td class="indent2">BX</td> <td>Involvement of bone marrow not assessed</td> </tr> <tr> <td class="indent2">B0</td> <td>No evidence of bone marrow involvement</td> </tr> <tr class="divider_bottom"> <td class="indent2">B1</td> <td>Lymphomatous infiltration of bone marrow</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Application</strong></td> </tr> <tr> <td class="indent2">TNM</td> <td>Clinical staging: status of tumor, node, metastasis, bone marrow</td> </tr> <tr> <td class="indent2">pTNMB</td> <td>Histopathological staging: status of tumor, node, metastasis, bone marrow</td> </tr> <tr class="divider_bottom"> <td class="indent2">pN</td> <td>The histological examination will ordinarily include 6 or more lymph nodes</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="2">Lugano staging system for gastrointestinal lymphomas<sup>[2]</sup></td> </tr> <tr> <td class="indent1" colspan="2"><strong>Stage I</strong> - The tumor is confined to the gastrointestinal tract. It can be a single primary lesion or multiple, noncontiguous lesions. (Corresponds to Paris stage T1-3 N0 M0.)</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Stage II</strong> - The tumor extends into the abdomen. This is further subdivided based upon the location of nodal involvement:</td> </tr> <tr> <td class="indent2" colspan="2"> <ul> <li>Stage II<sub>1</sub>: Involvement of local nodes (paragastric nodes for gastric lymphoma or para-intestinal nodes for intestinal lymphoma). (Corresponds to Paris stage T1-3 N1 M0.) </li> </ul> </td> </tr> <tr> <td class="indent2" colspan="2"> <ul> <li>Stage II<sub>2</sub>: Involvement of distant nodes (para-aortic, para-caval, pelvic, or inguinal nodes for most tumors; mesenteric nodes in the case of intestinal lymphoma). (Corresponds to Paris stage T1-3 N2 M0.) </li> </ul> </td> </tr> <tr> <td class="indent2" colspan="2"> <ul> <li>Stage IIE: The tumor penetrates the serosa to involve adjacent organs or tissues. (Corresponds to Paris stage T4 N0-2 M0.) </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2"><strong>Stage III</strong> - There is no stage III disease in this system.</td> </tr> <tr> <td class="indent1" colspan="2"><strong>Stage IV</strong> - There is disseminated extranodal involvement or concomitant supra-diaphragmatic nodal involvement. (Corresponds to Paris stage T1-4 N3 M0 or T1-4 N0-3 M1-2.)</td> </tr> </tbody></table></div><div class="graphic_footnotes">* Valid for lymphomas originating from the gastro-esophageal junction to the anus (as defined by identical histomorphological structure).<br/>¶ In case of more than one visible lesion synchronously originating in the gastrointestinal tract, give the characteristics of the more advanced lesion.<br/>Δ Anatomical designation of lymph nodes as "regional" according to site:

<ul>
<li>Stomach: perigastric nodes and those located along the ramifications of the coeliac artery (that is, left gastric artery, common hepatic artery, splenic artery) in accordance with compartments I and II of the Japanese Research Society for Gastric Cancer (1995).</li>
<li>Duodenum: pancreaticoduodenal, pyloric, hepatic, and superior mesenteric nodes.</li>
<li>Jejunum/ileum: mesenteric nodes and, for the terminal ileum only, the ileocolic as well as the posterior caecal nodes.</li>
<li>Colorectum: pericolic and perirectal nodes and those located along the ileocolic, right, middle, and left colic, inferior mesenteric, superior rectal, and internal iliac arteries.</li>
</ul></div><div class="graphic_reference">References:

<ol>
<li>Reproduced with permission from: Ruskoné-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52(6):912-913. Copyright © 2003 BMJ Publishing Group Ltd.</li>
<li>Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classification of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397. Copyright © 1994 Oxford University Press.</li>
</ol></div><div id="graphicVersion">Graphic 65686 Version 21.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
